本帖最后由 老马 于 2012-1-13 21:20 编辑
) r1 P6 x8 W/ ?5 P2 ?- }- D: `* X
爱必妥和阿瓦斯丁的比较
, [6 G" u7 g. w; @# w9 _8 c
0 {* y# W7 e4 e) C/ _/ e" t
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 |/ Q. K$ \- Y% C# ~6 J, M2 J
9 H' J1 _8 B6 t2 r( m1 N7 a+ g: ]
/ t8 `; p* r/ a! a g6 M2 r
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/; N9 R% I- a* L" m5 c
==================================================3 f3 U' m" n) h* G0 F. _# h1 x: d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)* W8 T1 H. c! a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 ^9 ~# O# r. z- X3 _ g
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; b: {+ S0 d8 B. g* e8 @2 A9 w
|
显身卡
5 c( S: \, ~" K' H5 f2 p
